Journal ArticleDOI
Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting.
Yanling Ren,Huifang Jiang,Fangjing Shi,Li Ye,Yingwan Luo,Xinping Zhou,Chen Mei,Liya Ma,Weilai Xu,Peipei Lin,Chao Hu,Jie Jin,Hongyan Tong +12 more
TLDR
15 mg/m2/d decitabine is associated with a lower incidence of hematological toxicities and longer OS and may be more suitable for patients with relatively lower risk.Abstract:
We retrospectively studied 133 myelodysplastic syndrome patients receiving decitabine during January 2009 and September 2017. The dose of 15 mg/m2/d (n = 83) and 20 mg/m2/d (n = 50) had comparable overall response rates (ORR) (51.8% vs. 52.00%) and complete remission rate (CRR) (15.66% vs. 22.00%). The 15 mg/m2/d group had a lower incidence of grade 3/4 neutropenia (60.24% vs. 88.00%, p < .05) and thrombocytopenia (65.06% vs. 88.00%, p < .05). The 15 mg/m2/d group had a longer median overall survival (OS) (21.60 months vs. 15.23 months, p = .02). The same results were seen in refractory anemia with excess blasts (RAEB) patients: The 15 mg/m2/d group also had comparable ORR, CRR, decreased hematological toxicities and longer OS. Further analysis suggested that survival benefit of 15 mg/m2/d group was mainly in those patients with lower risk stratification. In conclusion, 15 mg/m2/d decitabine is associated with a lower incidence of hematological toxicities and longer OS and may be more suitable for patients with relatively lower risk.read more
Citations
More filters
Journal ArticleDOI
Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis.
Jiang Ji,Miao Chen,Bing Han +2 more
TL;DR: HMA combined with chemotherapy can rescue the 2-year OS with less favorable cytogenetic stratification to some extent and for patients with similar older age and risk stratification, combination therapy even had a lower long-term OS regardless of the intensity of combined chemotherapy.
Journal ArticleDOI
Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective
Syed Saqib Ali,Ruchika Raj,Tejinder Kaur,Brenna Weadick,Debasis Nayak,Min Ji No,Jane Protos,Hannah Odom,Kajal Anantbhai Desai,Avinash Persaud,Joanne Wang,Raj Govindarajan +11 more
TL;DR: Recent developments in nucleoside transporters are reviewed, including their transport characteristics, their role in the regulation of hematopoiesis, and their potential involvement in the occurrence of adverse hematological side effects due to nucleosid drug treatment.
Journal ArticleDOI
Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases
Kaiji Zhang,Ying Lian,Xiaohong Guan,Qian Hu,Lihua Lei,Li Tao,Dong He,Juan Lin,Zheng Hou,Lirong Ren,Xiaoxiao Liu,Qian Ren,Lin Pan,Xiaoli Fei,Mei Xiong,Shunzhu Wen,Jinzhu Cao +16 more
TL;DR: It is demonstrated that a very-low-dose decitabine schedule has an appreciable response and survival rate, as well as appreciable tolerance and medical compliance for treating MDS.
References
More filters
Journal ArticleDOI
Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.
Xiao Li,Qiang Song,Yu Chen,Chunkang Chang,Dong Wu,Lingyun Wu,Jiying Su,Xi Zhang,Liyu Zhou,Lu-Xi Song,Zheng Zhang,Feng Xu,Ming Hou +12 more
TL;DR: The 15 mg/M2/d×5 day decitabine regimen was effective and safe for Chinese MDS patients with IPSS score of 0.5 or higher and contributed to zero therapy-related death and punctual course delivery, although III or IV grade of cytopenia was frequently observed.
Journal ArticleDOI
Myelodysplasia: new approaches.
TL;DR: The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and a risk of progression to acute myelogenous leukemia (AML).
[Inhibitory Effect of Decitabine on Proliferation of MDS-L Cells and Its Mechanism].
TL;DR: DAC can significantly suppress M DS-L cell proliferation, block MDS-L cells in G1 phase and induce the apoptosis at low concentration (0.1-0.2 µg/ml), and the effect was in dose- and- time-dependent manner.
Related Papers (5)
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Pau Montesinos,Gail J. Roboz,Claude Eric Bulabois,Marion Subklewe,Uwe Platzbecker,Yishai Ofran,Cristina Papayannidis,Agnieszka Wierzbowska,Ho Jin Shin,Vadim Doronin,Stefan Deneberg,Su-Peng Yeh,Mehmet Ali Özcan,Steven Knapper,Jorge E. Cortes,Daniel A. Pollyea,Gert J. Ossenkoppele,Sergio Giralt,Hartmut Döhner,Michael Heuser,Liang Xiu,Indrajeet Singh,Fei Huang,Julie S. Larsen,Andrew H. Wei +24 more
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Lübbert,Stefan Suciu,Liliana Baila,Björn Rüter,Uwe Platzbecker,Aristoteles Giagounidis,Dominik Selleslag,Boris Labar,Ulrich Germing,Helmut R. Salih,F. Beeldens,Petra Muus,Karl-Heinz Pflüger,Corneel Coens,Anne Hagemeijer,Hans E. Schaefer,Arnold Ganser,Carlo Aul,Theo de Witte,Pierre W. Wijermans +19 more